CASE LD0210 (NP)

P.2

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mall in an envelope addressed to the: Assistant

Commissioner for Patents, Washington, D.C. 20231.

Suzanne E. Babajko Type or print name

June 12, 2002

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SALVATI ET AL.

APPLICATION NO: 10/075,870 FILED: FEBRUARY 14, 2002

FOR: FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS

THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR

FUNCTION

Assistant Commissioner for Patents . Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the documents cited on the attached Form PTO-1449, copies of which are provided herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each document was considered by returning a copy of the initialed PTO 1449 Form.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4009

Date: June 12, 2002

Reg. No. 32,880

Attorney for Applicants

3

NO.182

CASE LD0210 (NP)

P.6

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Suzanne E. Babajko

Type or print name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SALVATI ET AL.

APPLICATION NO: 10/075,870 FILED: FEBRUARY 14, 2002

FOR: FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS

THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR

FUNCTION

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the documents cited on the attached form(s) PTO-1449. .

These documents were cited in a search report in a corresponding PCT International application. Copies of these documents and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each document was considered by returning a copy of the initialed PTO 1449 form(s).

Datajho

To date, Applicants have not received a first Office Action on the merits in connection with the present application. Should, however, such an Office Action have been mailed, please charge the fee set forth in §1.17(p) to Deposit Account No. 19-3880 of the undersigned.

Respectfully submitted,

Suzanne E. Babajko

Reg. No. 32,880

Attorney for Applicants

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4009

Date: August 20, 2002